{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T15:31:57Z","timestamp":1794238317793,"version":"4.9.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s12012-022-09721-1","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T05:03:06Z","timestamp":1642741386000},"page":"292-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":271,"title":["Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches"],"prefix":"10.1007","volume":"22","author":[{"given":"Mohammad","family":"Sheibani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf","family":"Nezamoleslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Eslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hadi","family":"Farjoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-5565","authenticated-orcid":false,"given":"Ahmad Reza","family":"Dehpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"9721_CR1","doi-asserted-by":"crossref","first-page":"117173","DOI":"10.1016\/j.lfs.2019.117173","volume":"241","author":"M Najafi","year":"2020","unstructured":"Najafi, M., Shayesteh, M. R. H., Mortezaee, K., Farhood, B., & Haghi-Aminjan, H. (2020). The role of melatonin on doxorubicin-induced cardiotoxicity: A systematic review. Life Sciences, 241, 117173.","journal-title":"Life Sciences"},{"key":"9721_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209\u2013249.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"9721_CR3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJM198107163050305","volume":"305","author":"RC Young","year":"1981","unstructured":"Young, R. C., Ozols, R. F., & Myers, C. E. (1981). The anthracycline antineoplastic drugs. New England Journal of Medicine, 305, 139\u2013153.","journal-title":"New England Journal of Medicine"},{"key":"9721_CR4","first-page":"313","volume":"1","author":"K Narkiewicz","year":"2016","unstructured":"Narkiewicz, K., Ratcliffe, L. E., Hart, E. C., Briant, L. J., Chrostowska, M., Wolf, J., Szyndler, A., Hering, D., Abdala, A. P., & Manghat, N. (2016). Unilateral carotid body resection in resistant hypertension: A safety and feasibility trial. JACC: Basic to Translational Science, 1, 313\u2013324.","journal-title":"JACC: Basic to Translational Science"},{"key":"9721_CR5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/HCO.0000000000000617","volume":"34","author":"BW Hardaway","year":"2019","unstructured":"Hardaway, B. W. (2019). Adriamycin-associated cardiomyopathy: Where are we now? Updates in pathophysiology, dose recommendations, prognosis, and outcomes. Current Opinion in Cardiology, 34, 289\u2013295.","journal-title":"Current Opinion in Cardiology"},{"key":"9721_CR6","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/bit.260110607","volume":"11","author":"F Arcamone","year":"1969","unstructured":"Arcamone, F., Cassinelli, G., Fantini, G., Grein, A., Orezzi, P., Pol, C., & Spalla, C. (1969). Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius. Biotechnology and Bioengineering, 11, 1101\u20131110.","journal-title":"Biotechnology and Bioengineering"},{"key":"9721_CR7","doi-asserted-by":"crossref","first-page":"101394","DOI":"10.1016\/j.redox.2019.101394","volume":"29","author":"B Kalyanaraman","year":"2020","unstructured":"Kalyanaraman, B. (2020). Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biology, 29, 101394.","journal-title":"Redox Biology"},{"key":"9721_CR8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.phymed.2018.01.009","volume":"40","author":"J Yu","year":"2018","unstructured":"Yu, J., Wang, C., Kong, Q., Wu, X., Lu, J.-J., & Chen, X. (2018). Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products. Phytomedicine, 40, 125\u2013139.","journal-title":"Phytomedicine"},{"key":"9721_CR9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/mol.119.115725","volume":"96","author":"N Wenningmann","year":"2019","unstructured":"Wenningmann, N., Knapp, M., Ande, A., Vaidya, T. R., & Ait-Oudhia, S. (2019). Insights into doxorubicin-induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring. Molecular Pharmacology, 96, 219\u2013232.","journal-title":"Molecular Pharmacology"},{"key":"9721_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/00003088-198815010-00002","volume":"15","author":"PA Speth","year":"1988","unstructured":"Speth, P. A., van Hoesel, Q. G., & Haanen, C. (1988). Clinical pharmacokinetics of doxorubicin. Clinical Pharmacokinetics, 15, 15\u201331. https:\/\/doi.org\/10.2165\/00003088-198815010-00002","journal-title":"Clinical Pharmacokinetics"},{"key":"9721_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Von Hoff","year":"1979","unstructured":"Von Hoff, D. D., Layard, M. W., Basa, P., Davis, H. L., Jr., Von Hoff, A. L., Rozencweig, M., & Muggia, F. M. (1979). Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine, 91, 710\u2013717. https:\/\/doi.org\/10.7326\/0003-4819-91-5-710","journal-title":"Annals of Internal Medicine"},{"key":"9721_CR12","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","volume":"266","author":"LJ Steinherz","year":"1991","unstructured":"Steinherz, L. J., Steinherz, P. G., Tan, C. T. C., Heller, G., & Murphy, M. L. (1991). Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA, 266, 1672\u20131677. https:\/\/doi.org\/10.1001\/jama.1991.03470120074036","journal-title":"JAMA"},{"key":"9721_CR13","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1200\/jco.2007.11.8877","volume":"26","author":"PA Ganz","year":"2008","unstructured":"Ganz, P. A., Hussey, M. A., Moinpour, C. M., Unger, J. M., Hutchins, L. F., Dakhil, S. R., Giguere, J. K., Goodwin, J. W., Martino, S., & Albain, K. S. (2008). Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897. Journal of Clinical Oncology, 26, 1223\u20131230. https:\/\/doi.org\/10.1200\/jco.2007.11.8877","journal-title":"Journal of Clinical Oncology"},{"key":"9721_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2021.100994","author":"A Avagimyan","year":"2021","unstructured":"Avagimyan, A., Mkrtchyan, L., Abrahomovich, O., Sheibani, M., Guevorkyan, A., Sarrafzadegan, N., Kozhukhov, S., Agati, L., Astengiano, R., Zaritska, V., & Jndoyan, Z. (2021). AC-mode of chemotherapy as a trigger of cardiac syndrome X: A case study. Current Problems in Cardiology. https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100994","journal-title":"Current Problems in Cardiology"},{"key":"9721_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13104-018-3260-6","volume":"11","author":"C Stark","year":"2018","unstructured":"Stark, C., Taimen, P., Savunen, T., & Koskenvuo, J. (2018). Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice. BMC Research Notes, 11, 148. https:\/\/doi.org\/10.1186\/s13104-018-3260-6","journal-title":"BMC Research Notes"},{"key":"9721_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1203\/00006450-198704010-00127","volume":"21","author":"RJ Boucek","year":"1987","unstructured":"Boucek, R. J., Kunkel, E. M., Graham, T. P., Brenner, D., & Olson, R. D. (1987). Doxorubicinol, the metabolite of doxorubucin, is more cardiotoxic than doxorubicin. Pediatric Research, 21, 187\u2013187. https:\/\/doi.org\/10.1203\/00006450-198704010-00127","journal-title":"Pediatric Research"},{"key":"9721_CR17","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1073\/pnas.85.10.3585","volume":"85","author":"RD Olson","year":"1988","unstructured":"Olson, R. D., Mushlin, P. S., Brenner, D. E., Fleischer, S., Cusack, B. J., Chang, B. K., & Boucek, R. J., Jr. (1988). Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proceedings of the National Academy of Sciences of the United States of America, 85, 3585\u20133589. https:\/\/doi.org\/10.1073\/pnas.85.10.3585","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9721_CR18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1139\/Y09-059","volume":"87","author":"AR Lehenbauer Ludke","year":"2009","unstructured":"Lehenbauer Ludke, A. R., Al-Shudiefat, A.A.-R.S., Dhingra, S., Jassal, D. S., & Singal, P. K. (2009). A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity. Canadian Journal of Physiology and Pharmacology, 87, 756\u2013763.","journal-title":"Canadian Journal of Physiology and Pharmacology"},{"key":"9721_CR19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.taap.2016.01.006","volume":"293","author":"M Pecoraro","year":"2016","unstructured":"Pecoraro, M., Del Pizzo, M., Marzocco, S., Sorrentino, R., Ciccarelli, M., Iaccarino, G., Pinto, A., & Popolo, A. (2016). Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity. Toxicology and applied pharmacology, 293, 44\u201352.","journal-title":"Toxicology and applied pharmacology"},{"key":"9721_CR20","doi-asserted-by":"crossref","first-page":"6534","DOI":"10.1111\/jcmm.15305","volume":"24","author":"N Osataphan","year":"2020","unstructured":"Osataphan, N., Phrommintikul, A., Chattipakorn, S. C., & Chattipakorn, N. (2020). Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: Insights for future interventions. Journal of Cellular and Molecular Medicine, 24, 6534\u20136557.","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"9721_CR21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1007094214460","volume":"207","author":"P Singal","year":"2000","unstructured":"Singal, P., Li, T., Kumar, D., Danelisen, I., & Iliskovic, N. (2000). Adriamycin-induced heart failure: Mechanisms and modulation. Molecular and Cellular Biochemistry, 207, 77\u201386.","journal-title":"Molecular and Cellular Biochemistry"},{"key":"9721_CR22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004). Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews, 56, 185\u2013229.","journal-title":"Pharmacological Reviews"},{"key":"9721_CR23","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.yjmcc.2006.06.009","volume":"41","author":"M Tokarska-Schlattner","year":"2006","unstructured":"Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., & Schlattner, U. (2006). New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics. Journal of Molecular and Cellular Cardiology, 41, 389\u2013405.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"9721_CR24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/taap.2002.9527","volume":"185","author":"E Aldieri","year":"2002","unstructured":"Aldieri, E., Bergandi, L., Riganti, C., Costamagna, C., Bosia, A., & Ghigo, D. (2002). Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation. Toxicology and Applied Pharmacology, 185, 85\u201390.","journal-title":"Toxicology and Applied Pharmacology"},{"key":"9721_CR25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4274\/Tjh.2012.0013","volume":"31","author":"A Bahad\u0131r","year":"2014","unstructured":"Bahad\u0131r, A., Kurucu, N., Kad\u0131o\u011flu, M., & Yenilme, E. (2014). The role of nitric oxide in Doxorubicin-induced cardiotoxicity: Experimental study. Turkish Journal of Hematology, 31, 68.","journal-title":"Turkish Journal of Hematology"},{"key":"9721_CR26","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1161\/01.CIR.0000146889.46519.27","volume":"110","author":"N Nozaki","year":"2004","unstructured":"Nozaki, N., Shishido, T., Takeishi, Y., & Kubota, I. (2004). Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation, 110, 2869\u20132874.","journal-title":"Circulation"},{"key":"9721_CR27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ejheart.2008.01.004","volume":"10","author":"A Riad","year":"2008","unstructured":"Riad, A., Bien, S., Gratz, M., Escher, F., Heimesaat, M. M., Bereswill, S., Krieg, T., Felix, S. B., Schultheiss, H. P., & Kroemer, H. K. (2008). Toll-like receptor-4 deficiency attenuates doxorubicin-induced cardiomyopathy in mice. European Journal of Heart Failure, 10, 233\u2013243.","journal-title":"European Journal of Heart Failure"},{"key":"9721_CR28","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1002\/ctm2.124","volume":"10","author":"C Hu","year":"2020","unstructured":"Hu, C., Zhang, X., Zhang, N., Wei, W. Y., Li, L. L., Ma, Z. G., & Tang, Q. Z. (2020). Osteocrin attenuates inflammation, oxidative stress, apoptosis, and cardiac dysfunction in doxorubicin-induced cardiotoxicity. Clinical and Translational Medicine, 10, e124.","journal-title":"Clinical and Translational Medicine"},{"key":"9721_CR29","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s12012-014-9305-8","volume":"15","author":"M Pecoraro","year":"2015","unstructured":"Pecoraro, M., Sorrentino, R., Franceschelli, S., Del Pizzo, M., Pinto, A., & Popolo, A. (2015). Doxorubicin-mediated cardiotoxicity: Role of mitochondrial connexin 43. Cardiovascular Toxicology, 15, 366\u2013376.","journal-title":"Cardiovascular Toxicology"},{"key":"9721_CR30","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","volume":"67","author":"YL Lyu","year":"2007","unstructured":"Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007). Topoisomerase II\u03b2\u2013mediated DNA double-strand breaks: Implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Research, 67, 8839\u20138846.","journal-title":"Cancer Research"},{"key":"9721_CR31","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/cvr\/cvq148","volume":"87","author":"T Horie","year":"2010","unstructured":"Horie, T., Ono, K., Nishi, H., Nagao, K., Kinoshita, M., Watanabe, S., Kuwabara, Y., Nakashima, Y., Takanabe-Mori, R., & Nishi, E. (2010). Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovascular Research, 87, 656\u2013664.","journal-title":"Cardiovascular Research"},{"key":"9721_CR32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.yjmcc.2004.12.013","volume":"38","author":"S Rohrbach","year":"2005","unstructured":"Rohrbach, S., Muller-Werdan, U., Werdan, K., Koch, S., Gellerich, N. F., & Holtz, J. (2005). Apoptosis-modulating interaction of the neuregulin\/erbB pathway with antracyclines in regulating Bcl-xS and Bcl-xL in cardiomyocytes. Journal of Molecular and Cellular Cardiology, 38, 485\u2013493.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"9721_CR33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejphar.2017.10.043","volume":"818","author":"K Renu","year":"2018","unstructured":"Renu, K., Abilash, V., & Arunachalam, S. (2018). Molecular mechanism of doxorubicin-induced cardiomyopathy\u2013An update. European Journal of Pharmacology, 818, 241\u2013253.","journal-title":"European Journal of Pharmacology"},{"key":"9721_CR34","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1161\/01.CIR.0000093196.59829.DF","volume":"108","author":"D Lebrecht","year":"2003","unstructured":"Lebrecht, D., Setzer, B., Ketelsen, U.-P., Haberstroh, J. R., & Walker, U. A. (2003). Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation, 108, 2423\u20132429.","journal-title":"Circulation"},{"key":"9721_CR35","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.bjp.0707294","volume":"151","author":"D Lebrecht","year":"2007","unstructured":"Lebrecht, D., Geist, A., Ketelsen, U. P., Haberstroh, J., Setzer, B., & Walker, U. (2007). Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. British Journal of Pharmacology, 151, 771\u2013778.","journal-title":"British Journal of Pharmacology"},{"key":"9721_CR36","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.taap.2010.01.006","volume":"244","author":"D Montaigne","year":"2010","unstructured":"Montaigne, D., Marechal, X., Baccouch, R., Modine, T., Preau, S., Zannis, K., Marchetti, P., Lancel, S., & Neviere, R. (2010). Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart. Toxicology and Applied Pharmacology, 244, 300\u2013307.","journal-title":"Toxicology and Applied Pharmacology"},{"key":"9721_CR37","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.freeradbiomed.2009.03.011","volume":"46","author":"EDB Danz","year":"2009","unstructured":"Danz, E. D. B., Skramsted, J., Henry, N., Bennett, J. A., & Keller, R. S. (2009). Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radical Biology and Medicine, 46, 1589\u20131597.","journal-title":"Free Radical Biology and Medicine"},{"key":"9721_CR38","doi-asserted-by":"publisher","first-page":"266ra170","DOI":"10.1126\/scitranslmed.3010189","volume":"6","author":"Y Liu","year":"2014","unstructured":"Liu, Y., Asnani, A., Zou, L., Bentley, V. L., Yu, M., Wang, Y., Dellaire, G., Sarkar, K. S., Dai, M., Chen, H. H., Sosnovik, D. E., Shin, J. T., Haber, D. A., Berman, J. N., Chao, W., & Peterson, R. T. (2014). Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Science Translational Medicine, 6, 266ra170. https:\/\/doi.org\/10.1126\/scitranslmed.3010189","journal-title":"Science Translational Medicine"},{"key":"9721_CR39","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1161\/01.cir.0000160359.49478.c2","volume":"111","author":"PW Fisher","year":"2005","unstructured":"Fisher, P. W., Salloum, F., Das, A., Hyder, H., & Kukreja, R. C. (2005). Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation, 111, 1601\u20131610. https:\/\/doi.org\/10.1161\/01.cir.0000160359.49478.c2","journal-title":"Circulation"},{"key":"9721_CR40","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jacbts.2016.10.006","volume":"2","author":"J Beak","year":"2017","unstructured":"Beak, J., Huang, W., Parker, J. S., Hicks, S. T., Patterson, C., Simpson, P. C., Ma, A., Jin, J., & Jensen, B. C. (2017). An oral selective alpha-1A adrenergic receptor agonist prevents doxorubicin cardiotoxicity. JACC. Basic to translational science, 2, 39\u201353. https:\/\/doi.org\/10.1016\/j.jacbts.2016.10.006","journal-title":"JACC. Basic to translational science"},{"key":"9721_CR41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0041-008X(92)90144-H","volume":"116","author":"DM Yourtee","year":"1992","unstructured":"Yourtee, D. M., Elkins, L. L., Nalvarte, E. L., & Smith, R. E. (1992). Amplification of doxorubicin mutagenicity by cupric ion. Toxicology and Applied Pharmacology, 116, 57\u201365.","journal-title":"Toxicology and Applied Pharmacology"},{"key":"9721_CR42","first-page":"217","volume":"11","author":"R Colombo","year":"1990","unstructured":"Colombo, R., Dalle Donne, I., & Milzani, A. (1990). Metal ions modulate the effect of doxorubicin on actin assembly. Cancer Biochemistry Biophysics, 11, 217\u2013226.","journal-title":"Cancer Biochemistry Biophysics"},{"key":"9721_CR43","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00059-011-3470-3","volume":"36","author":"Y Shi","year":"2011","unstructured":"Shi, Y., Moon, M., Dawood, S., McManus, B., & Liu, P. (2011). Mechanisms and management of doxorubicin cardiotoxicity. Herz, 36, 296\u2013305.","journal-title":"Herz"},{"key":"9721_CR44","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.jacc.2007.02.060","volume":"49","author":"GS Panjrath","year":"2007","unstructured":"Panjrath, G. S., Patel, V., Valdiviezo, C. I., Narula, N., Narula, J., & Jain, D. (2007). Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model. Journal of the American College of Cardiology, 49, 2457\u20132464.","journal-title":"Journal of the American College of Cardiology"},{"key":"9721_CR45","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/619185","author":"OA Al-Shabanah","year":"2012","unstructured":"Al-Shabanah, O. A., Aleisa, A. M., Hafez, M. M., Al-Rejaie, S. S., Al-Yahya, A. A., Bakheet, S. A., Al-Harbi, M. M., & Sayed-Ahmed, M. M. (2012). Desferrioxamine attenuates doxorubicin-induced acute cardiotoxicity through TFG-\/Smad p53 pathway in rat model. Oxidative Medicine and Cellular Longevity. https:\/\/doi.org\/10.1155\/2012\/619185","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"9721_CR46","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/BF00685548","volume":"31","author":"M Al-Harbi","year":"1992","unstructured":"Al-Harbi, M., Al-Gharably, N. M., Al-Shabanah, O. A., Al-Bekairi, A. M., Osman, A. M. M., & Tawfik, H. N. (1992). Prevention of doxorubicin-induced myocardial and haematological toxicities in rats by the iron chelator desferrioxamine. Cancer Chemotherapy and Pharmacology, 31, 200\u2013204.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"9721_CR47","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1139\/y11-020","volume":"89","author":"E-SM Ammar","year":"2011","unstructured":"Ammar, E.-S.M., Said, S. A., Suddek, G. M., & El-Damarawy, S. L. (2011). Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats. Canadian Journal of Physiology and Pharmacology, 89, 269\u2013276.","journal-title":"Canadian Journal of Physiology and Pharmacology"},{"key":"9721_CR48","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0006-2952(98)00102-6","volume":"56","author":"SA van Acker","year":"1998","unstructured":"van Acker, S. A., van Balen, G. P., van den Berg, D. J., Bast, A., & van der Vijgh, W. J. (1998). Influence of iron chelation on the antioxidant activity of flavonoids. Biochemical Pharmacology, 56, 935\u2013943.","journal-title":"Biochemical Pharmacology"},{"key":"9721_CR49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0891-5849(95)02047-0","volume":"20","author":"SA Van Acker","year":"1996","unstructured":"Van Acker, S. A., Tromp, M. N., Griffioen, D. H., Van Bennekom, W. P., Van Der Vijgh, W. J., & Bast, A. (1996). Structural aspects of antioxidant activity of flavonoids. Free Radical Biology and Medicine, 20, 331\u2013342.","journal-title":"Free Radical Biology and Medicine"},{"key":"9721_CR50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12012-007-0018-0","volume":"7","author":"A Bast","year":"2007","unstructured":"Bast, A., Haenen, G. R., Bruynzeel, A. M., & Van der Vijgh, W. J. (2007). Protection by flavonoids against anthracycline cardiotoxicity: From chemistry to clinical trials. Cardiovascular Toxicology, 7, 154\u2013159.","journal-title":"Cardiovascular Toxicology"},{"key":"9721_CR51","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00280-005-0083-7","volume":"57","author":"AM Willems","year":"2006","unstructured":"Willems, A. M., Bruynzeel, A. M., Kedde, M. A., Van Groeningen, C. J., Bast, A., & Van Der Vijgh, W. J. (2006). A phase I study of monohydroxyethylrutoside in healthy volunteers. Cancer Chemotherapy and Pharmacology, 57, 678\u2013684.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"9721_CR52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10565-006-0139-4","volume":"23","author":"A Bast","year":"2007","unstructured":"Bast, A., Kaiserov\u00e1, H., Den Hartog, G., Haenen, G., & Van Der Vijgh, W. (2007). Protectors against doxorubicin-induced cardiotoxicity: Flavonoids. Cell Biology and Toxicology, 23, 39\u201347.","journal-title":"Cell Biology and Toxicology"},{"key":"9721_CR53","first-page":"2497","volume":"44","author":"MJ Ehrke","year":"1984","unstructured":"Ehrke, M. J., Ryoyama, K., & Cohen, S. A. (1984). Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Research, 44, 2497\u20132504.","journal-title":"Cancer Research"},{"key":"9721_CR54","first-page":"3572","volume":"52","author":"DL Maccubbin","year":"1992","unstructured":"Maccubbin, D. L., Wing, K. R., Mace, K. F., Ho, R. L., Ehrke, M. J., & Mihich, E. (1992). Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Research, 52, 3572\u20133576.","journal-title":"Cancer Research"},{"key":"9721_CR55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/CAD.0000000000000299","volume":"27","author":"K Nagai","year":"2016","unstructured":"Nagai, K., Fukuno, S., Oda, A., & Konishi, H. (2016). Protective effects of taurine on doxorubicin-induced acute hepatotoxicity through suppression of oxidative stress and apoptotic responses. Anti-cancer Drugs, 27, 17\u201323.","journal-title":"Anti-cancer Drugs"},{"key":"9721_CR56","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1042\/bj20020752","volume":"367","author":"S Wang","year":"2002","unstructured":"Wang, S., Kotamraju, S., Konorev, E., Kalivendi, S., Joseph, J., & Kalyanaraman, B. (2002). Activation of nuclear factor-\u03baB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: The role of hydrogen peroxide. Biochemical Journal, 367, 729\u2013740.","journal-title":"Biochemical Journal"},{"key":"9721_CR57","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00280-019-04019-6","volume":"85","author":"M Sheibani","year":"2020","unstructured":"Sheibani, M., Nezamoleslami, S., Faghir-Ghanesefat, H., Hossein Emami, A., & Dehpour, A. R. (2020). Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats. Cancer Chemotherapy and Pharmacology, 85, 563\u2013571.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"9721_CR58","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.3892\/etm.2016.3518","volume":"12","author":"Z Sun","year":"2016","unstructured":"Sun, Z., Yan, B., Yu, W. Y., Yao, X., Ma, X., Sheng, G., & Ma, Q. (2016). Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation and apoptosis and the activation of FOXO3a. Experimental and Therapeutic Medicine, 12, 1879\u20131884.","journal-title":"Experimental and Therapeutic Medicine"},{"key":"9721_CR59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-017-0184-z","volume":"19","author":"RA Shaker","year":"2018","unstructured":"Shaker, R. A., Abboud, S. H., Assad, H. C., & Hadi, N. (2018). Enoxaparin attenuates doxorubicin induced cardiotoxicity in rats via interfering with oxidative stress, inflammation and apoptosis. BMC Pharmacology and Toxicology, 19, 1\u201310.","journal-title":"BMC Pharmacology and Toxicology"},{"key":"9721_CR60","first-page":"63","volume":"67","author":"MA Inchiosa Jr","year":"1990","unstructured":"Inchiosa, M. A., Jr., & Smith, C. M. (1990). Effects of ibuprofen on doxorubicin toxicity. Research Communications in Chemical Pathology and Pharmacology, 67, 63\u201378.","journal-title":"Research Communications in Chemical Pathology and Pharmacology"},{"key":"9721_CR61","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1159\/000356602","volume":"32","author":"R Guo","year":"2013","unstructured":"Guo, R., Wu, K., Chen, J., Mo, L., Hua, X., Zheng, D., Chen, P., Chen, G., Xu, W., & Feng, J. (2013). Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK\/NF\u03baB pathway in H9c2 cardiac cells. Cellular Physiology and Biochemistry, 32, 1668\u20131680.","journal-title":"Cellular Physiology and Biochemistry"},{"key":"9721_CR62","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/ptr.6882","volume":"35","author":"F Yarmohammadi","year":"2021","unstructured":"Yarmohammadi, F., Rezaee, R., & Karimi, G. (2021). Natural compounds against doxorubicin-induced cardiotoxicity: A review on the involvement of Nrf2\/ARE signaling pathway. Phytotherapy Research, 35, 1163\u20131175.","journal-title":"Phytotherapy Research"},{"key":"9721_CR63","first-page":"5721","volume":"15","author":"C Xiong","year":"2018","unstructured":"Xiong, C., Wu, Y. Z., Zhang, Y., Wu, Z. X., Chen, X. Y., Jiang, P., Guo, H. C., Xie, K. R., Wang, K. X., & Su, S. W. (2018). Protective effect of berberine on acute cardiomyopathy associated with doxorubicin treatment. Oncology Letters, 15, 5721\u20135729.","journal-title":"Oncology Letters"},{"key":"9721_CR64","doi-asserted-by":"crossref","first-page":"e0172803","DOI":"10.1371\/journal.pone.0172803","volume":"12","author":"MC Asensio-L\u00f3pez","year":"2017","unstructured":"Asensio-L\u00f3pez, M. C., Soler, F., Pascual-Figal, D., Fern\u00e1ndez-Belda, F., & Lax, A. (2017). Doxorubicin-induced oxidative stress: The protective effect of nicorandil on HL-1 cardiomyocytes. PLoS ONE, 12, e0172803.","journal-title":"PLoS ONE"},{"key":"9721_CR65","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/cr.2010.178","volume":"21","author":"MJ Morgan","year":"2011","unstructured":"Morgan, M. J., & Liu, Z. G. (2011). Crosstalk of reactive oxygen species and NF-\u03baB signaling. Cell Research, 21, 103\u2013115. https:\/\/doi.org\/10.1038\/cr.2010.178","journal-title":"Cell Research"},{"key":"9721_CR66","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.freeradbiomed.2014.03.001","volume":"72","author":"Y Zhao","year":"2014","unstructured":"Zhao, Y., Miriyala, S., Miao, L., Mitov, M., Schnell, D., Dhar, S. K., Cai, J., Klein, J. B., Sultana, R., Butterfield, D. A., Vore, M., Batinic-Haberle, I., Bondada, S., & St Clair, D. K. (2014). Redox proteomic identification of HNE-bound mitochondrial proteins in cardiac tissues reveals a systemic effect on energy metabolism after doxorubicin treatment. Free Radical Biology & Medicine, 72, 55\u201365. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2014.03.001","journal-title":"Free Radical Biology & Medicine"},{"key":"9721_CR67","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.3969\/j.issn.1673-5374.2013.21.009","volume":"8","author":"C Guo","year":"2013","unstructured":"Guo, C., Sun, L., Chen, X., & Zhang, D. (2013). Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regeneration Research, 8, 2003\u20132014. https:\/\/doi.org\/10.3969\/j.issn.1673-5374.2013.21.009","journal-title":"Neural Regeneration Research"},{"key":"9721_CR68","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00280-009-0932-x","volume":"64","author":"VA Sard\u00e3o","year":"2009","unstructured":"Sard\u00e3o, V. A., Oliveira, P. J., Holy, J., Oliveira, C. R., & Wallace, K. B. (2009). Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemotherapy and Pharmacology, 64, 811\u2013827. https:\/\/doi.org\/10.1007\/s00280-009-0932-x","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"9721_CR69","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1146\/annurev-pharmtox-011112-140320","volume":"53","author":"Q Ma","year":"2013","unstructured":"Ma, Q. (2013). Role of nrf2 in oxidative stress and toxicity. Annual Review of Pharmacology and Toxicology, 53, 401\u2013426. https:\/\/doi.org\/10.1146\/annurev-pharmtox-011112-140320","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"9721_CR70","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s00018-016-2223-0","volume":"73","author":"A Loboda","year":"2016","unstructured":"Loboda, A., Damulewicz, M., Pyza, E., Jozkowicz, A., & Dulak, J. (2016). Role of Nrf2\/HO-1 system in development, oxidative stress response and diseases: An evolutionarily conserved mechanism. Cellular and Molecular Life Sciences: CMLS, 73, 3221\u20133247. https:\/\/doi.org\/10.1007\/s00018-016-2223-0","journal-title":"Cellular and Molecular Life Sciences: CMLS"},{"key":"9721_CR71","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.freeradbiomed.2015.05.028","volume":"86","author":"P Singh","year":"2015","unstructured":"Singh, P., Sharma, R., McElhanon, K., Allen, C. D., Megyesi, J. K., Bene\u0161, H., & Singh, S. P. (2015). Sulforaphane protects the heart from doxorubicin-induced toxicity. Free Radical Biology & Medicine, 86, 90\u2013101. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.05.028","journal-title":"Free Radical Biology & Medicine"},{"key":"9721_CR72","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1615\/JEnvironPatholToxicolOncol.2019029341","volume":"38","author":"M Chen","year":"2019","unstructured":"Chen, M., Samuel, V. P., Wu, Y., Dang, M., Lin, Y., Sriramaneni, R., Sah, S. K., Chinnaboina, G. K., & Zhang, G. (2019). Nrf2\/HO-1 mediated protective activity of genistein against doxorubicin-induced cardiac toxicity. Journal of Environmental Pathology, Toxicology and Oncology, 38, 143\u2013152. https:\/\/doi.org\/10.1615\/JEnvironPatholToxicolOncol.2019029341","journal-title":"Journal of Environmental Pathology, Toxicology and Oncology"},{"key":"9721_CR73","doi-asserted-by":"publisher","first-page":"5923572","DOI":"10.1155\/2020\/5923572","volume":"2020","author":"X Cheng","year":"2020","unstructured":"Cheng, X., Liu, D., Xing, R., Song, H., Tian, X., Yan, C., & Han, Y. (2020). Orosomucoid 1 attenuates doxorubicin-induced oxidative stress and apoptosis in cardiomyocytes via Nrf2 signaling. BioMed Research International, 2020, 5923572. https:\/\/doi.org\/10.1155\/2020\/5923572","journal-title":"BioMed Research International"},{"key":"9721_CR74","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/cmar.s186696","volume":"11","author":"DS El-Agamy","year":"2019","unstructured":"El-Agamy, D. S., El-Harbi, K. M., Khoshhal, S., Ahmed, N., Elkablawy, M. A., Shaaban, A. A., & Abo-Haded, H. M. (2019). Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK\/NF-kB signaling pathways. Cancer Management and Research, 11, 47\u201361. https:\/\/doi.org\/10.2147\/cmar.s186696","journal-title":"Cancer Management and Research"},{"key":"9721_CR75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/jat.945","volume":"24","author":"E Fadillioglu","year":"2004","unstructured":"Fadillioglu, E., Oztas, E., Erdogan, H., Yagmurca, M., Sogut, S., Ucar, M., & Irmak, M. K. (2004). Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. Journal of Applied Toxicology: An International Journal, 24, 47\u201352.","journal-title":"Journal of Applied Toxicology: An International Journal"},{"key":"9721_CR76","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.fct.2010.01.005","volume":"48","author":"H Alkreathy","year":"2010","unstructured":"Alkreathy, H., Damanhouri, Z. A., Ahmed, N., Slevin, M., Ali, S. S., & Osman, A.-M.M. (2010). Aged garlic extract protects against doxorubicin-induced cardiotoxicity in rats. Food and Chemical Toxicology, 48, 951\u2013956.","journal-title":"Food and Chemical Toxicology"},{"key":"9721_CR77","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10787-019-00586-5","volume":"27","author":"M Sheibani","year":"2019","unstructured":"Sheibani, M., Faghir-Ghanesefat, H., Dehpour, S., Keshavarz-Bahaghighat, H., Sepand, M. R., Ghahremani, M. H., Azizi, Y., Rahimi, N., & Dehpour, A. R. (2019). Sumatriptan protects against myocardial ischaemia-reperfusion injury by inhibition of inflammation in rat model. Inflammopharmacology, 27, 1071\u20131080. https:\/\/doi.org\/10.1007\/s10787-019-00586-5","journal-title":"Inflammopharmacology"},{"key":"9721_CR78","doi-asserted-by":"publisher","first-page":"563","DOI":"10.22038\/ijbms.2019.33620.8020","volume":"22","author":"G Bazmandegan","year":"2019","unstructured":"Bazmandegan, G., Amirteimoury, M., Kaeidi, A., Shamsizadeh, A., Khademalhosseini, M., Nematollahi, M. H., Hassanipour, M., & Fatemi, I. (2019). Sumatriptan ameliorates renal injury induced by cisplatin in mice. Iranian Journal of Basic Medical Sciences, 22, 563\u2013567. https:\/\/doi.org\/10.22038\/ijbms.2019.33620.8020","journal-title":"Iranian Journal of Basic Medical Sciences"},{"key":"9721_CR79","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/fcp.12590","volume":"35","author":"F Eslami","year":"2021","unstructured":"Eslami, F., Rahimi, N., Ostovaneh, A., Ghasemi, M., Dejban, P., Abbasi, A., & Dehpour, A. R. (2021). Sumatriptan reduces severity of status epilepticus induced by lithium-pilocarpine through nitrergic transmission and 5-HT(1B\/D) receptors in rats: A pharmacological-based evidence. Fundamental & Clinical Pharmacology, 35, 131\u2013140. https:\/\/doi.org\/10.1111\/fcp.12590","journal-title":"Fundamental & Clinical Pharmacology"},{"key":"9721_CR80","doi-asserted-by":"publisher","DOI":"10.18502\/acta.v59i7.7020","author":"S Mohammad","year":"2021","unstructured":"Mohammad, S., Hedyeh, F.-G., Yaser, A., Tahmineh, M., Hasan, Y. M., Roya Sattarzadeh, B., Amir Hossein, E., & Ahmad Reza, D. (2021). Anti-inflammatory and antioxidative effects of sumatriptan against doxorubicin-induced cardiotoxicity in rat. Acta Medica Iranica. https:\/\/doi.org\/10.18502\/acta.v59i7.7020","journal-title":"Acta Medica Iranica"},{"key":"9721_CR81","first-page":"382","volume":"60","author":"M Iqbal","year":"2008","unstructured":"Iqbal, M., Dubey, K., Anwer, T., Ashish, A., & Pillai, K. K. (2008). Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacological Reports, 60, 382.","journal-title":"Pharmacological Reports"},{"key":"9721_CR82","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/01.cir.91.1.10","volume":"91","author":"N Siveski-Iliskovic","year":"1995","unstructured":"Siveski-Iliskovic, N., Hill, M., Chow, D. A., & Singal, P. K. (1995). Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation, 91, 10\u201315. https:\/\/doi.org\/10.1161\/01.cir.91.1.10","journal-title":"Circulation"},{"key":"9721_CR83","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1161\/01.cir.89.6.2829","volume":"89","author":"N Siveski-Iliskovic","year":"1994","unstructured":"Siveski-Iliskovic, N., Kaul, N., & Singal, P. K. (1994). Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation, 89, 2829\u20132835. https:\/\/doi.org\/10.1161\/01.cir.89.6.2829","journal-title":"Circulation"},{"key":"9721_CR84","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1006\/phrs.1999.0585","volume":"41","author":"MN Nagi","year":"2000","unstructured":"Nagi, M. N., & Mansour, M. A. (2000). Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: A possible mechanism of protection. Pharmacological Research, 41, 283\u2013289.","journal-title":"Pharmacological Research"},{"key":"9721_CR85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-4274(97)00028-3","volume":"92","author":"Y Sadzuka","year":"1997","unstructured":"Sadzuka, Y., Sugiyama, T., Shimoi, K., Kinae, N., & Hirota, S. (1997). Protective effect of flavonoids on doxorubicin-induced cardiotoxicity. Toxicology letters, 92, 1\u20137.","journal-title":"Toxicology letters"},{"key":"9721_CR86","doi-asserted-by":"crossref","first-page":"e8845","DOI":"10.7717\/peerj.8845","volume":"8","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y., Ma, C., Liu, C., & Wei, F. (2020). Luteolin attenuates doxorubicin-induced cardiotoxicity by modulating the PHLPP1\/AKT\/Bcl-2 signalling pathway. PeerJ, 8, e8845.","journal-title":"PeerJ"},{"key":"9721_CR87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1423-0127-20-1","volume":"20","author":"J-Y Chen","year":"2013","unstructured":"Chen, J.-Y., Hu, R.-Y., & Chou, H.-C. (2013). Quercetin-induced cardioprotection against doxorubicin cytotoxicity. Journal of Biomedical Science, 20, 1\u201311.","journal-title":"Journal of Biomedical Science"},{"key":"9721_CR88","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbadis.2007.05.002","volume":"1772","author":"H Kaiserov\u00e1","year":"2007","unstructured":"Kaiserov\u00e1, H., \u0160im\u016fnek, T., van der Vijgh, W. J., Bast, A., & Kvasni\u010dkov\u00e1, E. (2007). Flavonoids as protectors against doxorubicin cardiotoxicity: Role of iron chelation, antioxidant activity and inhibition of carbonyl reductase. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1772, 1065\u20131074.","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease"},{"key":"9721_CR89","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/0006-2952(89)90442-5","volume":"38","author":"MJ Laughton","year":"1989","unstructured":"Laughton, M. J., Halliwell, B., Evans, P. J., Robin, J., & Hoult, S. (1989). Antioxidant and pro-oxidant actions of the plant phenolics quercetin, gossypol and myricetin: Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA. Biochemical Pharmacology, 38, 2859\u20132865.","journal-title":"Biochemical Pharmacology"},{"key":"9721_CR90","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3389\/fphar.2019.01081","volume":"10","author":"D Chang","year":"2019","unstructured":"Chang, D., Li, H., Qian, C., & Wang, Y. (2019). Diohf protects against doxorubicin-induced cardiotoxicity through ERK1 signaling pathway. Frontiers in Pharmacology, 10, 1081.","journal-title":"Frontiers in Pharmacology"},{"key":"9721_CR91","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/506214","volume":"2012","author":"H Wang","year":"2012","unstructured":"Wang, H., Yu, P., Gou, H., Zhang, J., Zhu, M., Wang, Z. H., Tian, J. W., Jiang, Y. T., & Fu, F. H. (2012). Cardioprotective effects of 20(S)-ginsenoside Rh2 against doxorubicin-induced cardiotoxicity in vitro and in vivo. Evidence-Based Complementary and Alternative Medicine, 2012, 506214. https:\/\/doi.org\/10.1155\/2012\/506214","journal-title":"Evidence-Based Complementary and Alternative Medicine"},{"key":"9721_CR92","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.1158\/1078-0432.Ccr-07-1579","volume":"13","author":"L Li","year":"2007","unstructured":"Li, L., Pan, Q., Han, W., Liu, Z., Li, L., & Hu, X. (2007). Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. Clinical Cancer Research, 13, 6753\u20136760. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-07-1579","journal-title":"Clinical Cancer Research"},{"key":"9721_CR93","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1161\/CIRCULATIONAHA.108.799700","volume":"119","author":"W Zhu","year":"2009","unstructured":"Zhu, W., Soonpaa, M. H., Chen, H., Shen, W., Payne, R. M., Liechty, E. A., Caldwell, R. L., Shou, W., & Field, L. J. (2009). Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway. Circulation, 119, 99\u2013106. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.799700","journal-title":"Circulation"},{"key":"9721_CR94","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10557-020-06941-x","volume":"34","author":"KN Timm","year":"2020","unstructured":"Timm, K. N., & Tyler, D. J. (2020). The role of AMPK activation for cardioprotection in doxorubicin-induced cardiotoxicity. Cardiovascular Drugs and Therapy, 34, 255\u2013269. https:\/\/doi.org\/10.1007\/s10557-020-06941-x","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"9721_CR95","doi-asserted-by":"crossref","first-page":"e104888","DOI":"10.1371\/journal.pone.0104888","volume":"9","author":"LC Kobashigawa","year":"2014","unstructured":"Kobashigawa, L. C., Xu, Y. C., Padbury, J. F., Tseng, Y.-T., & Yano, N. (2014). Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: an in vitro study. PLoS ONE, 9, e104888.","journal-title":"PLoS ONE"},{"key":"9721_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23051184","author":"R Zilinyi","year":"2018","unstructured":"Zilinyi, R., Czompa, A., Czegledi, A., Gajtko, A., Pituk, D., Lekli, I., & Tosaki, A. (2018). The cardioprotective effect of metformin in doxorubicin-induced cardiotoxicity: The role of autophagy. Molecules (Basel, Switzerland). https:\/\/doi.org\/10.3390\/molecules23051184","journal-title":"Molecules (Basel, Switzerland)"},{"key":"9721_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.65","volume":"2","author":"J Huelsenbeck","year":"2011","unstructured":"Huelsenbeck, J., Henninger, C., Schad, A., Lackner, K. J., Kaina, B., & Fritz, G. (2011). Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death & Disease, 2, e190. https:\/\/doi.org\/10.1038\/cddis.2011.65","journal-title":"Cell Death & Disease"},{"key":"9721_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021). Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomedicine & Pharmacotherapy, 139, 111708. https:\/\/doi.org\/10.1016\/j.biopha.2021.111708","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"9721_CR99","doi-asserted-by":"publisher","first-page":"H1832","DOI":"10.1152\/ajpheart.01047.2009","volume":"298","author":"K Vedam","year":"2010","unstructured":"Vedam, K., Nishijima, Y., Druhan, L. J., Khan, M., Moldovan, N. I., Zweier, J. L., & Ilangovan, G. (2010). Role of heat shock factor-1 activation in the doxorubicin-induced heart failure in mice. American Journal of Physiology, Heart and Circulatory Physiology, 298, H1832\u2013H1841. https:\/\/doi.org\/10.1152\/ajpheart.01047.2009","journal-title":"American Journal of Physiology, Heart and Circulatory Physiology"},{"key":"9721_CR100","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.119.012338","volume":"8","author":"P Liu","year":"2019","unstructured":"Liu, P., Bao, H. Y., Jin, C. C., Zhou, J. C., Hua, F., Li, K., Lv, X. X., Cui, B., Hu, Z. W., & Zhang, X. W. (2019). Targeting extracellular heat shock protein 70 ameliorates doxorubicin-induced heart failure through resolution of toll-like receptor 2-mediated myocardial inflammation. Journal of the American Heart Association, 8, e012338. https:\/\/doi.org\/10.1161\/jaha.119.012338","journal-title":"Journal of the American Heart Association"},{"key":"9721_CR101","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/s0022-2828(03)00229-3","volume":"35","author":"YX Shan","year":"2003","unstructured":"Shan, Y. X., Liu, T. J., Su, H. F., Samsamshariat, A., Mestril, R., & Wang, P. H. (2003). Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. Journal of Molecular and Cellular Cardiology, 35, 1135\u20131143. https:\/\/doi.org\/10.1016\/s0022-2828(03)00229-3","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"9721_CR102","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2020.09.035","volume":"533","author":"D Zhao","year":"2020","unstructured":"Zhao, D., Xue, C., Li, J., Feng, K., Zeng, P., Chen, Y., Duan, Y., Zhang, S., Li, X., & Han, J. (2020). Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress. Biochemical and Biophysical Research Communications, 533, 304\u2013312.","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"9721_CR103","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3181\/0706-RM-152","volume":"233","author":"A Ramond","year":"2008","unstructured":"Ramond, A., Sartorius, E., Mousseau, M., Ribuot, C., & Joyeux-Faure, M. (2008). Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts. Experimental Biology and Medicine, 233, 76\u201383. https:\/\/doi.org\/10.3181\/0706-RM-152","journal-title":"Experimental Biology and Medicine"},{"key":"9721_CR104","doi-asserted-by":"publisher","first-page":"45126","DOI":"10.1038\/srep45126","volume":"7","author":"SM Man","year":"2017","unstructured":"Man, S. M., Karki, R., Briard, B., Burton, A., Gingras, S., Pelletier, S., & Kanneganti, T.-D. (2017). Differential roles of caspase-1 and caspase-11 in infection and inflammation. Scientific Reports, 7, 45126. https:\/\/doi.org\/10.1038\/srep45126","journal-title":"Scientific Reports"},{"key":"9721_CR105","doi-asserted-by":"publisher","first-page":"752","DOI":"10.21037\/cdt-19-707","volume":"10","author":"W Yu","year":"2020","unstructured":"Yu, W., Qin, X., Zhang, Y., Qiu, P., Wang, L., Zha, W., & Ren, J. (2020). Curcumin suppresses doxorubicin-induced cardiomyocyte pyroptosis via a PI3K\/Akt\/mTOR-dependent manner. Cardiovascular Diagnosis and Therapy, 10, 752\u2013769. https:\/\/doi.org\/10.21037\/cdt-19-707","journal-title":"Cardiovascular Diagnosis and Therapy"},{"key":"9721_CR106","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1124\/jpet.115.225375","volume":"355","author":"YL Chen","year":"2015","unstructured":"Chen, Y. L., Chung, S. Y., Chai, H. T., Chen, C. H., Liu, C. F., Chen, Y. L., Huang, T. H., Zhen, Y. Y., Sung, P. H., Sun, C. K., Chua, S., Lu, H. I., Lee, F. Y., Sheu, J. J., & Yip, H. K. (2015). Early administration of carvedilol protected against doxorubicin-induced cardiomyopathy. The Journal of Pharmacology and Experimental Therapeutics, 355, 516\u2013527. https:\/\/doi.org\/10.1124\/jpet.115.225375","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"9721_CR107","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2174\/138945011795378595","volume":"12","author":"A Dulhunty","year":"2011","unstructured":"Dulhunty, A., & Casarotto, B. (2011). The ryanodine receptor: A pivotal Ca2+ regulatory protein and potential therapeutic drug target. Current Drug Targets, 12, 709\u2013723.","journal-title":"Current Drug Targets"},{"key":"9721_CR108","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1161\/CIRCRESAHA.117.310355","volume":"121","author":"M Dewenter","year":"2017","unstructured":"Dewenter, M., von der Lieth, A., Katus, H. A., & Backs, J. (2017). Calcium signaling and transcriptional regulation in cardiomyocytes. Circulation Research, 121, 1000\u20131020.","journal-title":"Circulation Research"},{"key":"9721_CR109","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/toxsci\/kfy284","volume":"168","author":"AUR Aziz","year":"2019","unstructured":"Aziz, A. U. R., Geng, C., Li, W., Yu, X., Qin, K.-R., Wang, H., & Liu, B. (2019). Doxorubicin induces ER calcium release via Src in rat ovarian follicles. Toxicological Sciences, 168, 171\u2013178.","journal-title":"Toxicological Sciences"},{"key":"9721_CR110","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yjmcc.2012.03.006","volume":"52","author":"Y Octavia","year":"2012","unstructured":"Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012). Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology, 52, 1213\u20131225.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"9721_CR111","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejphar.2016.12.022","volume":"796","author":"F Yarmohmmadi","year":"2017","unstructured":"Yarmohmmadi, F., Rahimi, N., Faghir-Ghanesefat, H., Javadian, N., Abdollahi, A., Pasalar, P., Jazayeri, F., Ejtemaeemehr, S., & Dehpour, A. R. (2017). Protective effects of agmatine on doxorubicin-induced chronic cardiotoxicity in rat. European Journal of Pharmacology, 796, 39\u201344.","journal-title":"European Journal of Pharmacology"},{"key":"9721_CR112","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.lfs.2018.06.022","volume":"207","author":"M Khalilzadeh","year":"2018","unstructured":"Khalilzadeh, M., Abdollahi, A., Abdolahi, F., Abdolghaffari, A. H., Dehpour, A. R., & Jazaeri, F. (2018). Protective effects of magnesium sulfate against doxorubicin induced cardiotoxicity in rats. Life Sciences, 207, 436\u2013441.","journal-title":"Life Sciences"},{"key":"9721_CR113","doi-asserted-by":"crossref","first-page":"7025","DOI":"10.1073\/pnas.87.18.7025","volume":"87","author":"RA Gross","year":"1990","unstructured":"Gross, R. A., Moises, H. C., Uhler, M. D., & Macdonald, R. L. (1990). Dynorphin A and cAMP-dependent protein kinase independently regulate neuronal calcium currents. Proceedings of the National Academy of Sciences, 87, 7025\u20137029.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"9721_CR114","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1073\/pnas.84.15.5487","volume":"84","author":"RA North","year":"1987","unstructured":"North, R. A., Williams, J. T., Surprenant, A., & Christie, M. J. (1987). Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proceedings of the National Academy of Sciences, 84, 5487\u20135491.","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"9721_CR115","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s11033-020-06095-x","volume":"48","author":"NA Lashgari","year":"2021","unstructured":"Lashgari, N. A., Roudsari, N. M., Zandi, N., Pazoki, B., Rezaei, A., Hashemi, M., Momtaz, S., Rahimi, R., Shayan, M., Dehpour, A. R., & Abdolghaffari, A. H. (2021). Current overview of opioids in progression of inflammatory bowel disease; pharmacological and clinical considerations. Molecular Biology Reports, 48, 855\u2013874. https:\/\/doi.org\/10.1007\/s11033-020-06095-x","journal-title":"Molecular Biology Reports"},{"key":"9721_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107343","volume":"112","author":"G Zamanian","year":"2020","unstructured":"Zamanian, G., Shayan, M., Rahimi, N., Bahremand, T., Shafaroodi, H., Ejtemaei-Mehr, S., Aghaei, I., & Dehpour, A. R. (2020). Interaction of morphine tolerance with pentylenetetrazole-induced seizure threshold in mice: The role of NMDA-receptor\/NO pathway. Epilepsy & Behavior, 112, 107343. https:\/\/doi.org\/10.1016\/j.yebeh.2020.107343","journal-title":"Epilepsy & Behavior"},{"key":"9721_CR117","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tox.2007.09.026","volume":"243","author":"RB Kelishomi","year":"2008","unstructured":"Kelishomi, R. B., Ejtemaeemehr, S., Tavangar, S. M., Rahimian, R., Mobarakeh, J. I., & Dehpour, A. R. (2008). Morphine is protective against doxorubicin-induced cardiotoxicity in rat. Toxicology, 243, 96\u2013104.","journal-title":"Toxicology"},{"key":"9721_CR118","doi-asserted-by":"crossref","first-page":"a002576","DOI":"10.1101\/cshperspect.a002576","volume":"1","author":"DA Goodenough","year":"2009","unstructured":"Goodenough, D. A., & Paul, D. L. (2009). Gap junctions. Cold Spring Harbor Perspectives in Biology, 1, a002576.","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"key":"9721_CR119","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1540-8167.1994.tb01185.x","volume":"5","author":"NJ Severs","year":"1994","unstructured":"Severs, N. J. (1994). Pathophysiology of gap junctions in heart disease. Journal of Cardiovascular Electrophysiology, 5, 462\u2013475.","journal-title":"Journal of Cardiovascular Electrophysiology"},{"key":"9721_CR120","first-page":"1","volume":"16","author":"HN Siti","year":"2020","unstructured":"Siti, H. N., Jalil, J., Asmadi, A. Y., & Kamisah, Y. (2020). Effects of quercetin on cardiac function in pressure overload and postischemic cardiac injury in rodents: A systematic review and meta-analysis. Cardiovascular Drugs and Therapy, 16, 1\u201315.","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"9721_CR121","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/cvr\/cvu066","volume":"103","author":"W Srisakuldee","year":"2014","unstructured":"Srisakuldee, W., Makazan, Z., Nickel, B. E., Zhang, F., Thliveris, J. A., Pasumarthi, K. B., & Kardami, E. (2014). The FGF-2-triggered protection of cardiac subsarcolemmal mitochondria from calcium overload is mitochondrial connexin 43-dependent. Cardiovascular Research, 103, 72\u201380.","journal-title":"Cardiovascular Research"},{"key":"9721_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030757","author":"M Pecoraro","year":"2018","unstructured":"Pecoraro, M., Ciccarelli, M., Fiordelisi, A., Iaccarino, G., Pinto, A., & Popolo, A. (2018). Diazoxide improves mitochondrial connexin 43 expression in a mouse model of doxorubicin-induced cardiotoxicity. International Journal of Molecular Sciences. https:\/\/doi.org\/10.3390\/ijms19030757","journal-title":"International Journal of Molecular Sciences"},{"key":"9721_CR123","doi-asserted-by":"publisher","DOI":"10.1515\/jbcpp-2018-0212","author":"MG Elhadidy","year":"2020","unstructured":"Elhadidy, M. G., Elmasry, A., Rabei, M. R., & Eladel, A. E. (2020). Effect of ghrelin on VEGF-B and connexin-43 in a rat model of doxorubicin-induced cardiomyopathy. Journal of Basic and Clinical Physiology and Pharmacology. https:\/\/doi.org\/10.1515\/jbcpp-2018-0212","journal-title":"Journal of Basic and Clinical Physiology and Pharmacology"},{"key":"9721_CR124","doi-asserted-by":"crossref","first-page":"e26441","DOI":"10.1371\/journal.pone.0026441","volume":"6","author":"H Zhang","year":"2011","unstructured":"Zhang, H., Zhang, A., Guo, C., Shi, C., Zhang, Y., Liu, Q., Sparatore, A., & Wang, C. (2011). S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling. PLoS ONE, 6, e26441.","journal-title":"PLoS ONE"},{"key":"9721_CR125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20070140","volume":"404","author":"S Michan","year":"2007","unstructured":"Michan, S., & Sinclair, D. (2007). Sirtuins in mammals: Insights into their biological function. Biochemical Journal, 404, 1\u201313.","journal-title":"Biochemical Journal"},{"key":"9721_CR126","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fonc.2020.00474","volume":"10","author":"D Tomaselli","year":"2020","unstructured":"Tomaselli, D., Steegborn, C., Mai, A., & Rotili, D. (2020). Sirt4: A multifaceted enzyme at the crossroads of mitochondrial metabolism and cancer. Frontiers in Oncology, 10, 474.","journal-title":"Frontiers in Oncology"},{"key":"9721_CR127","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1515\/hsz-2016-0316","volume":"398","author":"VW Dolinsky","year":"2017","unstructured":"Dolinsky, V. W. (2017). The role of sirtuins in mitochondrial function and doxorubicin-induced cardiac dysfunction. Biological Chemistry, 398, 955\u2013974.","journal-title":"Biological Chemistry"},{"key":"9721_CR128","doi-asserted-by":"crossref","first-page":"10981","DOI":"10.1074\/jbc.M114.607960","volume":"290","author":"KG Cheung","year":"2015","unstructured":"Cheung, K. G., Cole, L. K., Xiang, B., Chen, K., Ma, X., Myal, Y., Hatch, G. M., Tong, Q., & Dolinsky, V. W. (2015). Sirtuin-3 (SIRT3) protein attenuates doxorubicin-induced oxidative stress and improves mitochondrial respiration in H9c2 cardiomyocytes. Journal of Biological Chemistry, 290, 10981\u201310993.","journal-title":"Journal of Biological Chemistry"},{"key":"9721_CR129","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3892\/etm.2016.3437","volume":"12","author":"MH Liu","year":"2016","unstructured":"Liu, M. H., Shan, J., Li, J., Zhang, Y., & Lin, X. L. (2016). Resveratrol inhibits doxorubicin-induced cardiotoxicity via sirtuin 1 activation in H9c2 cardiomyocytes. Experimental and Therapeutic Medicine, 12, 1113\u20131118.","journal-title":"Experimental and Therapeutic Medicine"},{"key":"9721_CR130","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1159\/000373937","volume":"35","author":"Y Ruan","year":"2015","unstructured":"Ruan, Y., Dong, C., Patel, J., Duan, C., Wang, X., Wu, X., Cao, Y., Pu, L., Lu, D., & Shen, T. (2015). SIRT1 suppresses doxorubicin-induced cardiotoxicity by regulating the oxidative stress and p38MAPK pathways. Cellular Physiology and Biochemistry, 35, 1116\u20131124.","journal-title":"Cellular Physiology and Biochemistry"},{"key":"9721_CR131","doi-asserted-by":"crossref","first-page":"34082","DOI":"10.18632\/oncotarget.16133","volume":"8","author":"VB Pillai","year":"2017","unstructured":"Pillai, V. B., Kanwal, A., Fang, Y. H., Sharp, W. W., Samant, S., Arbiser, J., & Gupta, M. P. (2017). Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice. Oncotarget, 8, 34082.","journal-title":"Oncotarget"},{"key":"9721_CR132","first-page":"1212","volume":"20","author":"DM Needham","year":"2004","unstructured":"Needham, D. M., Shufelt, K. A., Tomlinson, G., Scholey, J. W., & Newton, G. E. (2004). Troponin I and T levels in renal failure patients without acute coronary syndrome: A systematic review of the literature. The Canadian Journal of Cardiology, 20, 1212\u20131218.","journal-title":"The Canadian Journal of Cardiology"},{"key":"9721_CR133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ircmb.2015.09.002","volume":"321","author":"J-P Jin","year":"2016","unstructured":"Jin, J.-P. (2016). Evolution, regulation, and function of N-terminal variable region of troponin T: Modulation of muscle contractility and beyond. International Review of Cell and Molecular Biology, 321, 1\u201328.","journal-title":"International Review of Cell and Molecular Biology"},{"key":"9721_CR134","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0940-2993(11)80297-6","volume":"47","author":"H Bleuel","year":"1995","unstructured":"Bleuel, H., Deschl, U., Bertsch, T., B\u00f6lz, G., & Rebel, W. (1995). Diagnostic efficiency of troponin T measurements in rats with experimental myocardial cell damage. Experimental and Toxicologic Pathology, 47, 121\u2013127.","journal-title":"Experimental and Toxicologic Pathology"},{"key":"9721_CR135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408369709038215","volume":"34","author":"J Mair","year":"1997","unstructured":"Mair, J., & Apple, F. (1997). Progress in myocardial damage detection: New biochemical markers for clinicians. Critical Reviews in Clinical Laboratory Sciences, 34, 1\u201366.","journal-title":"Critical Reviews in Clinical Laboratory Sciences"},{"key":"9721_CR136","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejphar.2010.05.046","volume":"641","author":"M Rahimi Balaei","year":"2010","unstructured":"Rahimi Balaei, M., Momeny, M., Babaeikelishomi, R., Ejtemaei Mehr, S., Tavangar, S. M., & Dehpour, A. R. (2010). The modulatory effect of lithium on doxorubicin-induced cardiotoxicity in rat. European Journal of Pharmacology, 641, 193\u2013198. https:\/\/doi.org\/10.1016\/j.ejphar.2010.05.046","journal-title":"European Journal of Pharmacology"},{"key":"9721_CR137","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3340\/jkns.2018.0222","volume":"62","author":"EA Chang","year":"2019","unstructured":"Chang, E. A., Jin, S. W., Nam, M. H., & Kim, S. D. (2019). Human induced pluripotent stem cells: Clinical significance and applications in neurologic diseases. Journal of Korean Neurosurgical Society, 62, 493\u2013501. https:\/\/doi.org\/10.3340\/jkns.2018.0222","journal-title":"Journal of Korean Neurosurgical Society"},{"key":"9721_CR138","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2174\/1389201021666200422090952","volume":"21","author":"T Matsui","year":"2020","unstructured":"Matsui, T., Miyamoto, N., Saito, F., & Shinozawa, T. (2020). Molecular profiling of human induced pluripotent stem cell-derived cells and their application for drug safety study. Current Pharmaceutical Biotechnology, 21, 807\u2013828. https:\/\/doi.org\/10.2174\/1389201021666200422090952","journal-title":"Current Pharmaceutical Biotechnology"},{"key":"9721_CR139","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah5457","author":"HD Devalla","year":"2018","unstructured":"Devalla, H. D., & Passier, R. (2018). Cardiac differentiation of pluripotent stem cells and implications for modeling the heart in health and disease. Science Translational Medicine. https:\/\/doi.org\/10.1126\/scitranslmed.aah5457","journal-title":"Science Translational Medicine"},{"key":"9721_CR140","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1016\/j.celrep.2018.08.079","volume":"24","author":"K Blinova","year":"2018","unstructured":"Blinova, K., Dang, Q., Millard, D., Smith, G., Pierson, J., Guo, L., Brock, M., Lu, H. R., Kraushaar, U., Zeng, H., Shi, H., Zhang, X., Sawada, K., Osada, T., Kanda, Y., Sekino, Y., Pang, L., Feaster, T. K., Kettenhofen, R., \u2026 Gintant, G. (2018). International multisite study of human-induced pluripotent stem cell-derived cardiomyocytes for drug proarrhythmic potential assessment. Cell Reports, 24, 3582\u20133592. https:\/\/doi.org\/10.1016\/j.celrep.2018.08.079","journal-title":"Cell Reports"},{"key":"9721_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.00050","author":"V Schwach","year":"2020","unstructured":"Schwach, V., Slaats, R. H., & Passier, R. (2020). Human pluripotent stem cell-derived cardiomyocytes for assessment of anticancer drug-induced cardiotoxicity. Frontiers in Cardiovascular Medicine. https:\/\/doi.org\/10.3389\/fcvm.2020.00050","journal-title":"Frontiers in Cardiovascular Medicine"},{"key":"9721_CR142","doi-asserted-by":"publisher","first-page":"25333","DOI":"10.1038\/srep25333","volume":"6","author":"A Maillet","year":"2016","unstructured":"Maillet, A., Tan, K., Chai, X., Sadananda, S. N., Mehta, A., Ooi, J., Hayden, M. R., Pouladi, M. A., Ghosh, S., Shim, W., & Brunham, L. R. (2016). Modeling doxorubicin-induced cardiotoxicity in human pluripotent stem cell derived-cardiomyocytes. Science and Reports, 6, 25333. https:\/\/doi.org\/10.1038\/srep25333","journal-title":"Science and Reports"},{"key":"9721_CR143","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nm.4087","volume":"22","author":"PW Burridge","year":"2016","unstructured":"Burridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S. G., Sharma, A., Holmstr\u00f6m, A., Chang, A. C., Coronado, M. J., Ebert, A. D., Knowles, J. W., Telli, M. L., Witteles, R. M., Blau, H. M., Bernstein, D., Altman, R. B., & Wu, J. C. (2016). Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nature Medicine, 22, 547\u2013556. https:\/\/doi.org\/10.1038\/nm.4087","journal-title":"Nature Medicine"},{"key":"9721_CR144","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1111\/jcmm.14346","volume":"23","author":"N Cui","year":"2019","unstructured":"Cui, N., Wu, F., Lu, W. J., Bai, R., Ke, B., Liu, T., Li, L., Lan, F., & Cui, M. (2019). Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase II\u03b1 to II\u03b2 in human stem cell derived cardiomyocytes. Journal of Cellular and Molecular Medicine, 23, 4627\u20134639. https:\/\/doi.org\/10.1111\/jcmm.14346","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"9721_CR145","doi-asserted-by":"publisher","first-page":"44735","DOI":"10.1038\/srep44735","volume":"7","author":"L Zhao","year":"2017","unstructured":"Zhao, L., & Zhang, B. (2017). Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes. Science and Reports, 7, 44735. https:\/\/doi.org\/10.1038\/srep44735","journal-title":"Science and Reports"},{"key":"9721_CR146","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41420-019-0182-6","volume":"5","author":"KM McSweeney","year":"2019","unstructured":"McSweeney, K. M., Bozza, W. P., Alterovitz, W.-L., & Zhang, B. (2019). Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity. Cell Death Discovery, 5, 102. https:\/\/doi.org\/10.1038\/s41420-019-0182-6","journal-title":"Cell Death Discovery"},{"key":"9721_CR147","doi-asserted-by":"publisher","first-page":"19626","DOI":"10.1073\/pnas.1904979116","volume":"116","author":"J Li","year":"2019","unstructured":"Li, J., Wang, P. Y., Long, N. A., Zhuang, J., Springer, D. A., Zou, J., Lin, Y., Bleck, C. K. E., Park, J. H., Kang, J. G., & Hwang, P. M. (2019). p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proceedings of the National Academy of Sciences of the United States of America, 116, 19626\u201319634. https:\/\/doi.org\/10.1073\/pnas.1904979116","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"9721_CR148","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1186\/1471-2407-14-842","volume":"14","author":"S Deng","year":"2014","unstructured":"Deng, S., Yan, T., Jendrny, C., Nemecek, A., Vincetic, M., G\u00f6dtel-Armbrust, U., & Wojnowski, L. (2014). Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms. BMC Cancer, 14, 842. https:\/\/doi.org\/10.1186\/1471-2407-14-842","journal-title":"BMC Cancer"},{"key":"9721_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00178","author":"RE Ahmed","year":"2020","unstructured":"Ahmed, R. E., Anzai, T., Chanthra, N., & Uosaki, H. (2020). A brief review of current maturation methods for human induced pluripotent stem cells-derived cardiomyocytes. Frontiers in Cell and Developmental Biology. https:\/\/doi.org\/10.3389\/fcell.2020.00178","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"9721_CR150","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cotox.2020.04.001","volume":"23\u201324","author":"L Pang","year":"2020","unstructured":"Pang, L. (2020). Toxicity testing in the era of induced pluripotent stem cells: A perspective regarding the use of patient-specific induced pluripotent stem cell\u2013derived cardiomyocytes for cardiac safety evaluation. Current Opinion in Toxicology, 23\u201324, 50\u201355. https:\/\/doi.org\/10.1016\/j.cotox.2020.04.001","journal-title":"Current Opinion in Toxicology"},{"key":"9721_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.774389","author":"Y Soma","year":"2021","unstructured":"Soma, Y., Morita, Y., Kishino, Y., Kanazawa, H., Fukuda, K., & Tohyama, S. (2021). The present state and future perspectives of cardiac regenerative therapy using human pluripotent stem cells. Frontiers in Cardiovascular Medicine. https:\/\/doi.org\/10.3389\/fcvm.2021.774389","journal-title":"Frontiers in Cardiovascular Medicine"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-022-09721-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-022-09721-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-022-09721-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T21:34:05Z","timestamp":1700084045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-022-09721-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":151,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["9721"],"URL":"https:\/\/doi.org\/10.1007\/s12012-022-09721-1","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"8 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol of this study was approved by the Ethics Committee of Tehran University of Medical Sciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.Consent for PublicationNot applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}